These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22232346)

  • 1. Daclizumab use in patients with pediatric multiple sclerosis.
    Gorman MP; Tillema JM; Ciliax AM; Guttmann CR; Chitnis T
    Arch Neurol; 2012 Jan; 69(1):78-81. PubMed ID: 22232346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
    Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
    Sheridan JP; Robinson RR; Rose JW
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.
    Rose JW; Watt HE; White AT; Carlson NG
    Ann Neurol; 2004 Dec; 56(6):864-7. PubMed ID: 15499632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
    Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
    Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N; Martin R
    Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
    Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
    BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M; Milo R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
    Martin R
    Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
    Waubant E; Chabas D; Okuda DT; Glenn O; Mowry E; Henry RG; Strober JB; Soares B; Wintermark M; Pelletier D
    Arch Neurol; 2009 Aug; 66(8):967-71. PubMed ID: 19667217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
    Baldassari LE; Rose JW
    Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Daclizumab: Clinical trial of monoclonal antibody for the treatment of MS].
    Kreutzkamp B
    Med Monatsschr Pharm; 2014 Jun; 37(6):202-6; quiz 207-8. PubMed ID: 25051810
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
    Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.